Difference between revisions of "Methoxsalen (Uvadex)"
m |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Psoralen/furocoumarin. Photoactive substance used for palliative photopheresis/extracorporeal phototherapy of cutaneous T-cell lymphoma (CTCL). Exact mechanism of action unknown, but photoactivation of methoxsalen is believed to result in its conjugation and formation of covalent bonds with DNA and possibly proteins. Additions to single strands of DNA and crosslinking of methoxsalen to two strands of DNA occur.<ref name="insert">[http://www.therakos.com/sites/default/files/pdf/us-package-insert.pdf Methoxsalen (Uvadex) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/methoxsalen.pdf Methoxsalen (Uvadex) package insert (locally hosted backup)]</ref><ref>[http://www.therakos.com/healthcare-professionals Therakos manufacturer's website]</ref> | Class/mechanism: Psoralen/furocoumarin. Photoactive substance used for palliative photopheresis/extracorporeal phototherapy of cutaneous T-cell lymphoma (CTCL). Exact mechanism of action unknown, but photoactivation of methoxsalen is believed to result in its conjugation and formation of covalent bonds with DNA and possibly proteins. Additions to single strands of DNA and crosslinking of methoxsalen to two strands of DNA occur.<ref name="insert">[http://www.therakos.com/sites/default/files/pdf/us-package-insert.pdf Methoxsalen (Uvadex) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/methoxsalen.pdf Methoxsalen (Uvadex) package insert (locally hosted backup)]</ref><ref>[http://www.therakos.com/healthcare-professionals Therakos manufacturer's website]</ref> | ||
| Line 10: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Cutaneous T-cell lymphoma]] |
==Patient drug information== | ==Patient drug information== | ||
| Line 17: | Line 15: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 2/25/1999: Initial FDA approval "for extracorporeal administration with the UVAR Photopheresis System in the palliative treatment of the skin manifestations of [[T-cell lymphoma | cutaneous T-cell lymphoma (CTCL)]] that is unresponsive to other forms of treatment." | + | * 2/25/1999: Initial FDA approval "for extracorporeal administration with the UVAR Photopheresis System in the palliative treatment of the skin manifestations of [[cutaneous T-cell lymphoma | cutaneous T-cell lymphoma (CTCL)]] that is unresponsive to other forms of treatment." |
| − | * 10/31/2013: Indication revised "for extracorporeal administration with the UVAR™ XTS™ or THERAKOS™ CELLEX™ Photopheresis System in the palliative | + | * 10/31/2013: Indication revised "for extracorporeal administration with the UVAR™ XTS™ or THERAKOS™ CELLEX™ Photopheresis System in the palliative treatment of the skin manifestations of [[cutaneous T-cell lymphoma | cutaneous T-cell lymphoma (CTCL)]] that is unresponsive to other forms of treatment." |
| − | treatment of the skin manifestations of [[T-cell lymphoma | | ||
| + | ==Also known as== | ||
| + | Photopheresis systems that methoxsalen is used with may be called UVAR XTS, Therakos, or Therakos Cellex. Other formulations of methoxsalen may be known as 8-MOP, Deltasoralen, Meladinine, Oxsoralen ultra, Ultramop, or xanthotoxin. | ||
| + | |||
==References== | ==References== | ||
<references/> | <references/> | ||
| Line 26: | Line 26: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| + | [[Category:Intravenous chemotherapy]] | ||
| − | [[Category:T-cell lymphoma medications]] | + | [[Category:Cutaneous T-cell lymphoma medications]] |
[[Category:Drugs FDA approved in 1999]] | [[Category:Drugs FDA approved in 1999]] | ||
Revision as of 17:03, 21 July 2017
General information
Class/mechanism: Psoralen/furocoumarin. Photoactive substance used for palliative photopheresis/extracorporeal phototherapy of cutaneous T-cell lymphoma (CTCL). Exact mechanism of action unknown, but photoactivation of methoxsalen is believed to result in its conjugation and formation of covalent bonds with DNA and possibly proteins. Additions to single strands of DNA and crosslinking of methoxsalen to two strands of DNA occur.[1][2][3]
Route: IV (other formulations of methoxsalen also available in PO & topical forms)
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Patient information about Therakos photopheresis[4]
- Methoxsalen (Uvadex) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2/25/1999: Initial FDA approval "for extracorporeal administration with the UVAR Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment."
- 10/31/2013: Indication revised "for extracorporeal administration with the UVAR™ XTS™ or THERAKOS™ CELLEX™ Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment."
Also known as
Photopheresis systems that methoxsalen is used with may be called UVAR XTS, Therakos, or Therakos Cellex. Other formulations of methoxsalen may be known as 8-MOP, Deltasoralen, Meladinine, Oxsoralen ultra, Ultramop, or xanthotoxin.